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INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most common
malignancy in childhood, accounting for approximately 25%
of all pediatric malignancies. More than 250 children are newly
diagnosed ALL every year in Korea. It is well established that
the identification of cytogenetic abnormalities is very useful
for the prediction of outcome in childhood ALL. For example,
t(9;22), 11q23 abnormalities, and hypodiploidy are known to
confer a poor prognosis, and t(12;21), hyperdiploidy are asso-
ciated with a favorable outcome (1). The association between
the deletion of 9p21 and poor prognosis was suggested (2-4).
However, questions about the relationship between t(12;21)
and good prognosis have arisen because several patients with
TEL/AML1 fusion showed poorer clinical outcome if other
gene rearrangements coexist (5, 6). 
Although detection of chromosome aberrations in ALL has
been improved by the development of cytogenetic techniques
in conventional G-banding analysis, prognostically important
structural or numerical chromosome aberrations may frequent-
ly go undetected using conventional G-banding alone due to
poor chromosome morphology and few malignant metaphas-
es (7, 8). Especially, 9p abnormalities, t(12;21), and some of
the 11q23 rearrangements are very difficult, or even impos-
sible, to detect by conventional G-banding analysis. Inter-
phase fluorescence in situ hybridization (FISH) is a rapid and
sensitive tool for detecting gene rearrangements, and thus has
been frequently used at the time of diagnosis and during fol-
low-up of patients to monitor minimal residual disease.
There have been few Korean studies evaluating the inci-
dences of BCR/ABL, MLL, TEL/AML1, and p16 gene rear-
rangements commonly found in childhood ALL because FISH
has not yet been routinely used at diagnosis of childhood ALL.
Therefore, we cannot confirm the results suggesting the exis-
tence of geographical variations in the incidence of TEL/AML1
fusion (9, 10). 
In the present study, we performed FISH with probes for
BCR/ABL, MLL, TEL/AML1 rearrangements, and p16 dele-
tions for each case of childhood ALL. The aims of this study
were to estimate the incidences of different genetic subgroups
with abnormalities involving the above genes in Korean child-
hood ALL, to identify new abnormalities, and to demonstrate
the usefulness of FISH.
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Molecular Cytogenetic Analysis of Gene Rearrangements in Childhood
Acute Lymphoblastic Leukemia
The aims of this study were to estimate the incidences of BCR/ABL, MLL, TEL/AML1
rearrangements, and p16 deletions in childhood acute lymphoblastic leukemia
(ALL), to identify new abnormalities, and to demonstrate the usefulness of inter-
phase fluorescence in situ hybridization (FISH). We performed G-banding analysis
and FISH using probes for BCR/ABL, MLL, TEL/AML1 rearrangements, and p16
deletions on 65 childhood ALL patients diagnosed and uniformly treated at a sin-
gle hospital. Gene rearrangements were identified in 73.8% of the patients using
the combination of G-banding and FISH, while the chromosomal abnormalities
were identified in 49.2% using G-banding alone. Gene rearrangements were dis-
closed by FISH in 24 (72.7%) of 33 patients with normal karyotype or no mitotic
cell in G-banding. Among the gene rearrangements detected by FISH, the most
common gene rearrangement was p16 deletion (20.3%) and the incidences of
others were 14.1% for TEL/AML1, 11.3% for MLL, and 1.8% for BCR/ABL translo-
cations. Infrequent or new aberrations such as AML1 amplification, MLL deletion,
ABL deletion, and TEL/AML1 fusion with AML1 deletion were also observed. We
established the rough incidences of gene rearrangements in childhood ALL, found
new abnormalities and demonstrated the diagnostic capability of interphase FISH
to identify cryptic chromosome aberrations.
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MATERIALS AND METHODS
Patients
Among patients diagnosed childhood ALL between 1997
and 2002 at the Samsung Medical Center in Seoul, Korea, 65
patients, whose bone marrow cells had been stored at initial
diagnosis and were available for cytogenetic analysis, were
studied. The male-female ratio was 1.24 and all patients were
treated according to the Children’s Cancer Study Group (CCG)
protocol. The median age at diagnosis was five years (range,
3 months-15 yr). The leukemia immunophenotype was deter-
mined by standard immunofluorescence analysis using a panel
of monoclonal antibodies. Patients were classified into three
risk groups by prognostic factors such as age, sex, white blood
cell (WBC) count, immunophenotype, and other findings
(Table 1). A institutional ethical committee approved this
study.
Conventional G-banding analyses 
Cell culture and chromosome preparation were performed
according to two different protocols: synchronized and unsyn-
chronized techniques in parallel. Synchronization was accom-
plished using methotrexate. Standard cytogenetic prepara-
tions were made. At least 20 metaphases were analyzed using
Giemsa-trypsin staining. Karyotypes were interpreted accord-
ing to the International System for Cytogenetic Nomencla-
ture (ISCN) (11). 
Interphase fluorescence in situ hybridization (FISH) 
The selected probes were LSI BCR/ABL ES (extra signal)
Dual Color Translocation Probe (Vysis Inc., Downers Grove,
IL, U.S.A.), LSI TEL/AML1 ES Dual Color Translocation
Probe (Vysis), MLL Dual Color Break Apart Rearrangement
Probe (Vysis), and LSI p16/centromere enumeration probe
(CEP) 9 Dual Color Probe (Vysis). FISH was performed accord-
ing to the manufacturer’s instructions. The image was ana-
lyzed using Cytovision (Applied Imaging International Ltd.,
Newcastle, England). At least 200 interphase nuclei were
analyzed for each case, and if needed, the metaphases were
also analyzed. Nuclei with ambiguous signals were exclud-
ed from analysis.
To determine cut-off values of each gene rearrangement, we
analyzed 20 bone marrow specimens from patients without
evidence of hematologic malignancies or solid tumors by
FISH. Each cut-off was set at mean proportion of cells with
rearrangements plus 3×standard deviations. The cut-off
values were as follows: 1.5% for BCR/ABL translocation;
1.0% for MLL translocation; 3.4% for MLL deletion; 1.5%
for TEL/AML1 translocation; 3.1% for p16 deletion.
RESULTS
Cytogenetic investigations were performed by convention-
al G-banding analysis for all cases and by interphase FISH
using probes to detect BCR/ABL rearrangements (57 cases),
TEL/AML1 rearrangements (64 cases), MLL rearrangements
(62 cases), and p16 deletions (64 cases). Numerical and/or
structural aberrations were identified in 73.8% of all cases
by the combination of conventional G-banding and inter-
phase FISH, while abnormalities were detected in 49.2% of
the cases using G-banding alone. Gene rearrangements were
disclosed by FISH in 24 (72.7%) of 33 patients who showed
a normal banded karyotype or no mitotic cell in G-banding.
Among 30 cases harboring structural abnormalities identified
by FISH, only three cases showed chromosome aberrations sug-
gesting the FISH results in G-banding analysis (two patients
with 11q23 abnormalities and one patient with translocation
involving 12p12). Twenty-one patients (32.3%) including
two who had been classified as low-risk group but later had
relapsed, had prognostically unfavorable gene rearrangements
that had not been previously detected by G-banding analysis.
The most common gene rearrangement was p16 deletion
(20.3%) and the incidences of others were 14.1% for TEL/
AML1, 11.3% for MLL, and 1.8% for BCR/ABL transloca-
tions (Table 2). 
Five cases showed the coexistence of more than two gene
Other findings
and/
or
WBC count 
at diagnosis
(/ L)
and/
or
Age at
diagnosis
(yr)
Risk group
Low 2-9 or <10,000 -
Intermediate 1-2 and <50,000 -
2-9 and 10,000-50,000 and boys with platelet
count 100,000/ L
High 2-9 and <50,000 -
≥10 or ≥50,000 or lymphomatous
<1 features
Burkitt type
infant leukemia
Table 1. Criteria for the assignment of risk group in childhood
acute lymphoblastic leukemia
Translocation Deletion Amplification
No. of patients (%) Gene
rearrangements
BCR/ABL 1 (1.8) ABL: 1 (1.8) -
MLL 7 (11.3) 2 (3.2) -
TEL/AML1 9* (14.1) TEL
� : 1 (1.6),  AML1: 1 (1.6)
AML1
� : 4 (6.3)
p16 - 14 (20.3) -
*Two cases had two TEL/AML1 translocations. 
� Deletions were accompanied by TEL/AML1 translocations. 
Table 2. Frequencies and types of gene rearrangements iden-
tified by FISH analysis38 H.Y. Woo, D.W. Kim, H. Park, et al.
rearrangements. Three cases showed p16 deletions in com-
bination with other gene rearrangements: one case had MLL
deletion, TEL/AML1 translocation, and p16 hemizygous dele-
tion; one had MLL translocation and p16 hemizygous dele-
tion; and the other had t(8;14) with p16 homozygous dele-
tion. The other two cases had TEL/AML1 fusions accompa-
nied by rearrangements of non-translocated TEL gene. Table
3 describes the patients with gene rearrangements.
ABL deletion 
One case displayed only one ABL signal with two BCR sig-
nals in 199 of 200 interphase cells (Fig. 1A). The karyotype
was 46,XY,del(5)(q32q34). Considering the presence of both
signals from the p16 and CEP9 in the p16/CEP9 FISH anal-
ysis, this finding indicated deletion of the ABL gene rather
than monosomy 9.
*One case was died after relapse. 
� One case was lost on follow up. T, translocation; amp, amplification; del, deletion; +/-, hemizygous deletion; -/-,
homozygous deletion.
+/- -/- TT  + TEL del T +AML1 del AML1 amp T del T ABL del
MLL rearrangements TEL/AML1 rearrangements p16 deletion BCR/ABL rearrangements
Parameter
All patients 1 1 7 2 9 1 4 1 6 8
Males 1 1 4 1 3 1 - 1 3 4
Females - - 3 1 6 - 4 - 3 4
Age <1 or ≥10 yr - 1 1 - 1 1 - 1 2 2
1≤ age <10 yr 1 - 6 2 8 - 4 - 4 6
WBC ≥50,000/ L - 1 3 - - - - - 4 3
WBC < 50,000/ L 1 - 3 2 9 1 4 1 2 5
T-ALL - 1 - - - - - - 1 3
Precursor-B ALL 1 - 7 2 9 1 4 1 5 5
High risk 1 1 6 1 1 1 - 1 4 5
Intermediate risk - - 1 - 5 - 3 - 1 1
Low risk - - - 1 3 1 1 - 1 2
Death - - 2* - - - -
� -1 * -
Relapse - - 2 - - - -
� -2 1
Table 3. Summary of clinical characteristics of childhood ALL patients with gene rearrangements
Fig. 1. Abnormal signal patterns in FISH analysis. (A) One ABL gene locus is deleted and both BCR genes are present as indicated by
one orange and two green signals (1O2G), respectively. (B) Only one fusion signal indicating deletion of one MLL gene. (C) Two TEL/AML1
fusion signals (2O1G2F) indicating double fusion genes. (D) A TEL/AML1 fusion with TEL deletion (2O1F). (E) TEL/AML1 fusion with AML1
deletion (1O1G1F). (F) More than five orange signals indicating AML1 gene amplification are present. (G) A nucleus containing p16
hemizygous deletion showing one orange and two green signals (1O2G). (H) A nucleus containing p16 homozygous deletion showing
two green signals without orange signals (2G).
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MLL rearrangements 
Two different types of MLL gene rearrangements were ob-
served in FISH analysis; translocation and deletion. Six of
seven cases with MLL translocations showed no chromosome
abnormality involving 11q23 in G-banding analysis. Two
cases including one with del(11)(q23) in G-banding, showed
only one fusion (orange/green) signal in 19% and 41% of 200
interphase cells, respectively (Fig. 1B). Consequently, a large
deletion occurring proximal to the MLL breakpoint was sug-
gested. The possibility of monosomy 11 could be excluded
because FISH using the CEP11 confirmed the presence of
both chromosome 11. 
TEL/AML1 rearrangements 
TEL/AML1 translocations were found in nine (14.1%) of
64 patients and none showed t(12;21) in G-banding analy-
sis. Two fusion signals were observed in two cases (Fig. 1C).
Two patients (3.1%) with TEL/AML1 fusion had another
structural rearrangement involving non-translocated 12p13
breakpoint. One had reciprocal translocation involving 12p12
and 14q21, and the other had deletion of non-translocated
TEL gene (Fig. 1D). The proportion of the cells with signals
suggesting TEL/AML1 fusion with TEL deletion was 64%
of 200 interphase cells. When we performed FISH using the
CEP12, 9.0% of 200 cells showed one CEP12 signal and thus
we excluded the occurrence of TEL/AML1 fusion in clones
with monosomy 12. Four patients showed the loss of one
AML1 signal in addition to the TEL/AML1 fusion (Fig. 1E). 
AML1 amplification 
One case displayed more than five AML1 signals localized
in a very defined chromosomal region in 45% of 200 inter-
phase cells, strongly suggestive of intrachromosomal ampli-
fication of the AML1 gene (Fig. 1F).
p16 deletions 
The combined incidence of hemizygous and/or homozygous
deletions determined here was 20.3%. None with p16 dele-
tions had 9p21 abnormalities in G-banding analysis. Homozy-
gous deletions were observed in eight cases (12.5%) and hem-
izygous deletions in six cases (9.4%). One case had both in
two different cell populations. p16 deletions were significant-
ly more common among T-lineage ALL (T-ALL) patients than
among precursor-B ALL patients (57.1% vs. 17.2%, p<0.05).
Associations between the gene rearrangements and 
clinical features or outcomes 
Seven patients were lost on follow-up. All patients except
four succeeded in attaining complete remission after induc-
tion chemotherapy. Five patients died and seven relapsed.
Allogeneic bone marrow transplantations were done in nine
patients. 
Due to the small number of patients in each genetic sub-
group and the short duration of follow-up, we did not analyze
the relationship between the outcome and each gene rearrange-
ment. However, eight of fourteen patients with unfavorable
outcome showed MLL translocations or p16 deletions.
DISCUSSION
We performed FISH with probes for BCR/ABL, MLL,
TEL/AML1 rearrangements, and p16 deletions to estimate
the incidences of different genetic subgroups with abnormali-
ties involving above genes in Korean childhood ALL, to iden-
tify new abnormalities, and to demonstrate the usefulness of
FISH. A significant increase in detection rate from 49.2%
to 73.8% was observed using the combination of convention-
al G-banding and interphase FISH analysis. Especially of note,
FISH was useful to identify the cryptic gene rearrangements
in cases with normal banded karyotype or no mitotic cell in
G-banding. The conventional G-banding analysis was able
to identify the structural abnormalities in few patients with
positive FISH results. Moreover, FISH revealed unfavorable
gene rearrangements in two patients who had been treated
following the protocol for low or intermediate-risk group and
eventually relapsed. Therefore, performing FISH at diagno-
sis would be important to acquire prognostically important
information in childhood ALL. 
Compared with incidences of other regions, the incidences
of TEL/AML1 translocation and p16 homozygous deletion
appeared a little lower in our study. The incidence of TEL/
AML1 fusion was 14.1% of total childhood ALL and 15.8%
of precursor-B ALL in this study. Incidence of around 25%
was reported in the United States (12, 13), Germany (14),
Italy (14), and France (15). Although differences in technique,
criteria for acceptance, and criteria for inclusion in the stud-
ies may account for many of these variations, our results also
supported the existence of geographical differences in genetic
propensity for TEL/AML1 fusion in childhood ALL (9, 10,
16). The incidence of p16 homozygous deletion was 42.9% in
T-ALL and 8.6% in precursor-B ALL, lower than that report-
ed (64% in T-ALL and 23% in precursor-B ALL) (17). How-
ever, the higher frequency in T-ALL was concordant with pre-
vious report (17). 
Frequent rearrangements of non-translocated TEL gene were
observed in more than 50% of the patients with TEL/AML1
fusion (8, 15, 18), which supports the theory that the TEL/
AML1 fusion gene acts in a recessive manner with regard to
TEL gene, or that the secondary genetic changes including
rearrangements of non-translocated TEL gene are needed in
leukemogenesis by TEL/AML1 fusion (19, 20). However,
only two (22.2%) cases among nine with TEL/AML1 fusion40 H.Y. Woo, D.W. Kim, H. Park, et al.
showed simultaneous rearrangements of non-translocated TEL
gene in our study. This may be due to the relatively low sen-
sitivity of the FISH method. By using molecular genetic
methods such as RT-PCR, loss of heterozygosity (LOH) anal-
ysis, and spectral karyotyping (SKY), the detection of non-
translocated TEL gene rearrangements will be increased. The
design of new FISH probes similar to the MLL break-apart
probe could be proposed for simultaneous detection of both
the translocation and deletion of non-translocated TEL gene.
One patient with non-translocated TEL deletion was classi-
fied into the high-risk group, whereas other patients with
TEL/AML1 fusion alone were classified into low- or inter-
mediate-risk group in our study. Although the clinical sig-
nificance of TEL deletion is unclear, this finding suggests a
certain role for TEL deletion in the progression of the dis-
ease (5, 21). Therefore, investigation for the rearrangements
of non-translocated TEL gene in patients with TEL/AML1
fusion will be helpful for predicting the prognosis. 
Among nine patients with TEL/AML1 fusions, two showed
double fusion signals. One displayed trisomy 21 in G-band-
ing analysis and we assumed that the additional chromosome
21 might be not the normal chromosome but the der(21)
t(12;21). It was also reported that the additional fusion sig-
nals resulted from duplication of der(21)t(12;21) or ider(21)
(q10)t(12;21) (10). Because the TEL/AML1 fusion transcript
encodes a strong repressor that interferes with AML1-depen-
dent transcription activation and the wild-type TEL gene,
the two fusion transcripts may result in increased expression
of the TEL/AML1 fusion gene and increased silencing of the
wild-type TEL gene (19, 22). In support of this hypothesis,
extra copies of der(21)t(12;21) were found more frequently
among patients suffering from relapse (23); our case had dele-
tion of non-translocated TEL.
A large proportion of presumptive del(11)(q23) or del(11)
(q23q25) might represent previously unidentified translo-
cations that could be detected by FISH (24, 25). However,
our patient with del(11)(q23) in G-banding analysis had also
deletion of the MLL gene in FISH. Our two patients with
MLL deletions showed relatively longer survival, which was in
concordance with the report that MLL deletion was associat-
ed with good prognosis (25). As different prognoses between
the patients with MLL translocation and those with MLL
deletion were reported, FISH would be needed in patients
with del(11)(q23) in G-banding analysis.
New findings observed in this study were the deletions of
the ABL and AML1 gene. Deletion of ABL was observed in
a 13-yr-old boy with T-ALL. Deletions of the 9q34 region
on which the ABL gene is located have been known to be quite
common findings in several solid tumors (26, 27). However,
the deletions of 9q34 have rarely been found in ALL and thus
the clinical significance is unknown. Searching for identical
cases and additional follow-up study of our case will be help-
ful in understanding the role of ABL deletion in leukemo-
genesis of ALL. As well, deletion of AML1 was accompanied
with TEL/AML1 fusion and observed in four female patients
with precursor-B ALL, which has not yet been reported. It
was unclear whether the deletion occurred at der(21) or at
normal chromosome 21. The loss of 21q was not observed in
patients with TEL/AML1 fusion, while the gain of 21q was
frequently found (19). As such, we assumed that the deletions
might occur at the der(21) and the AML1 deletion would be
one of the secondary genetic changes required in leukemoge-
nesis by TEL/AML1 fusion. 
Amplification of the AML1 gene was observed in a 10-yr-
old male patient with precursor-B ALL. Since first reported
(28), ten patients with AML1 amplification have been sub-
sequently reported (7, 29-32). All cases had childhood precur-
sor-B ALL. One of ten showed TEL/AML1 fusion and none
showed TEL deletion. Although six cases were initially clas-
sified into the high-risk group, all but one remained alive
without relapse. Our case also remained alive without events.
AML1 amplification was suggested that play an important
role in leukemogenesis as a target event in a trisomy 21 or a
21q22 amplicon (31). Further studies are needed to know
the role of amplification of the AML1 gene in leukemogen-
esis of ALL. 
The frequent presence of TEL and p16 rearrangements in
the company of other genetic changes suggested that the rear-
rangements of tumor suppressor genes might contribute to
leukemogenesis in cooperation with other genetic changes,
possibly by amplifying the malignant potential. 
In conclusion, routine performance of interphase FISH using
BCR/ABL, MLL, TEL/AML1, and p16 probes at diagnosis
would be very useful to establish accurate prognosis and to
monitor the minimal residual disease in childhood ALL. Fur-
ther study with a larger number of patients would be neces-
sary to know the relationship between the outcome and each
gene rearrangement and to provide a better understanding
of leukemogenesis by new gene rearrangements identified in
this study.
REFERENCES
1. Ma SK, Wan TS, Chan LC. Cytogenetics and molecular genetics of
childhood leukemia. Hematol Oncol 1999; 17: 91-105. 
2. Kees UR, Burton PR, Lu C, Baker DL. Homozygous deletion of the
p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associ-
ated with unfavorable clinical outcome. Blood 1997; 89: 4161-6.
3. Heerema NA, Sather HN, Sensel MG, Liu-Mares W, Lange BJ, Bos-
trom BC, Nachman JB, Steinherz PG, Hutchinson R, Gaynon PS,
Arthur DC, Uckun FM. Association of chromosome arm 9p abnor-
malities with adverse risk in childhood acute lymphoblastic leukemia:
a report from the children’s cancer group. Blood 1999; 94: 1537-44.
4. Carter TL, Watt PM, Kumar R, Burton PR, Reaman GH, Sather HN,
Baker DL, Kees UR. Hemizygous p16
INK4A deletion in pediatric acute
lymphoblastic leukemia predicts independent risk of relapse. Blood
2001; 97: 572-4.
. .Gene Rearrangements in Childhood ALL 41
5. Wiemels JL, Ford AM, Van Wering ER, Postma A, Greaves M. Pro-
tracted and variable latency of acute lymphoblastic leukemia after
TEL-AML1 gene fusion in utero. Blood 1999; 94: 1057-62.
6. Anguita E, Gonzalez FA, Lopez J, Villegas A. TEL/AML1 transcript
and p16 gene deletion in a patient with childhood acute lymphoblas-
tic leukemia. Br J Haematol 1997; 99: 240-1.
7. Nordgren A, Schoumans J, Soderhall S, Nordenskjold M, Blennow
E. Interphase fluorescence in situ hybridization and spectral karyotyp-
ing reveals hidden genetic aberrations in children with acute lym-
phoblastic leukemia and a normal banded karyotype. Br J Haema-
tol 2001; 114: 786-93.
8. Nordgren A, Heyman M, Sahlen S, Schoumans J, Soderhall S, Nor-
denskjold M, Blennow E. Spectral karyotyping and interphase FISH
reveal abnormalities not detected by conventional G-banding. Eur J
Haematol 2002; 68: 31-41.
9. Garcia-Sanz R, Alaejos I, Orfao A, Rasillo A, Chillon MC, Tabernero
MD, Mateos MV, Lopez-Perez R, Gonzalez D, Balanzategui A, Gon-
zalez M, San Miguel JF. Low frequency of the TEL/AML1 fusion
gene in acute lymphoblastic leukemia in Spain. Br J Haematol 1999;
107: 667-9.
10. Andreasson P, Hoglund M, Bekassy AN, Garwicz S, Heldrup J, Mitel-
man F, Johansson B. Cytogenetic and FISH studies of a single cen-
ter consecutive series of 152 childhood acute lymphoblastic leukemias.
Eur J Haematol 2000; 65: 40-51.
11. Mitelman F (ed) ISCN. An international system for human cytoge-
netic nomenclature. Tennessee, S Karger: Basel, 1995. 
12. McLean TW, Ringold S, Neuberg D, Stegmaier K, Tantravahi R,
Ritz J, Koeffler HP, Takeuchi S, Janssen JW, Seriu T, Bartram CR,
Sallan SE, Gilliland DG, Golub TR. TEL/AML-1 dimerizes and is
associated with a favorable outcome in childhood acute lymphoblas-
tic leukemia. Blood 1996; 88: 4252-8.
13. Rubnitz JE, Shuster JJ, Land VJ, Link MP, Pullen DJ, Camitta BM,
Pui CH, Downing JR, Behm FG. Case-control study suggests a favor-
able impact of TEL rearrangement in patients with B lineage acute
lymphoblastic leukemia treated with antimetabolite based therapy:
a Pediatric Oncology Group study. Blood 1997; 89: 1143-6.
14. Borkhardt A, Cazzaniga G, Viehmann S, Valsecchi MG, Ludwig
WD, Burci L, Mangioni S, Schrappe M, Riehm H, Lampert F, Basso
G, Masera G, Garbott J, Biondi A. Incidence and clinical relevance
of TEL/AML1 fusion genes in children with acute lymphoblastic leu-
kemia enrolled in the German and Italian multicenter therapy trials.
Blood 1997; 90: 571-7.
15. Cave H, Cacheux V, Raynaud S, Brunie G, Bakkus M, Cochaux P,
Preudhomme C, Lai JL, Vilmer E, Grandchamp B. ETV6 is the tar-
get of chromosome 12p deletions in t(12;21) childhood acute lym-
phocytic leukemia. Leukemia 1997; 11: 1459-64.
16. Park KU, She CJ, Shin HY, Ahn HS, Kim CJ, Cho BK, Cho HI, Lee
DS. Low incidence of TEL/AML1 fusion and TEL deletion in Korean
childhood acute leukemia by extra-signal fluorescence in situ hybri-
dization. Cancer Genet Cytogenet 2001; 126: 73-7.
17. Drexler HG. Review of alterations of the cyclin dependent kinase in-
hibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-
lymphoma cells. Leukemia 1998; 12: 845-59.
18. Raynaud S, Cavee H, Baens M, Shurtleff SA, Mathew S, Raimondi
S. The 12;21 translocation involving TEL and deletion of the other
TEL allele: two frequently associated alterations found in childhood
acute lymphoblastic leukemia. Blood 1996; 87: 2891-9.
19. Raynaud SD, Dastugue N, Zoccola D, Shurtleff SA, Mathew S, Rai-
mondi SC. Cytogenetic abnormalities associated with the t(12;21).
A collaborative study of 169 children with t(12;21)-positive acute
lymphoblastic leukemia. Leukemia 1999; 13: 1325-30.
20. Kempski HM, Sturt NT. The TEL-AML1 fusion accompanied by loss
of the untranslocated TEL allele in B-precursor acute lymphoblas-
tic leukemia of childhood. Leukemia Lymphoma 2000; 40: 39-47.
21. Kim DH, Moldwin RL, Vignon C, Bohlander SK, Suto Y, Giordano
L, Gupta R, Fears S, Nucifora G, Rowley JD, Smith SD. TEL-AML1
translocations with TEL and CDKN2 inactivation in acute lympho-
blastic leukemia cell lines. Blood 1996; 88: 785-94.
22. Inamdar N, Kumar SA, Banavali SD, Advani S, Magrath I, Bhatia
K. Comparative incidence of the rearrangements of TEL/AML1 and
ALL1 genes in pediatric precursor B acute lymphoblastic leukemias
in India. Int J Oncol 1998; 13: 1319-22. 
23. Loncarevic IF, Roltzheim B, Ritterbach J, Viehmann S, Borkhardt
A, Lampert F, Harbott J. Trisomy 21 is a recurrent secondary aber-
ration in childhood acute lymphoblastic leukemia with TEL/AML1
gene fusion. Genes Chromosomes Cancer 1999; 24: 272-7.
24. Kobayashi H, Espinosa R III, Thirman MJ, Fernald AA, Shannon
K, Diaz MO, Le Beau MM, Rowley JD. Do terminal deletions of
11q23 exist? Identification of undetected translocations with fluo-
rescence in situ hybridization. Genes Chrom Cancer 1993; 7: 204-8.
25. Harbott J, Mancini M, Verellen-Dumoulin C, Moorman AV, Seck-
er-Walker LM. Hematological malignancies with a deletion of 11q23:
cytogenetic and clinical aspects. Leukemia 1998; 12: 823-7.
26. Devlin J, Elder PA, Gabra H, Steel CM, Knowles MA. High frequen-
cy of chromosome 9 deletion in ovarian cancer: evidence for three
tumour suppressor loci. Br J Cancer 1996; 73: 420-3.
27. Takita J, Hayashi Y, Kohno T, Yamaguchi N, Hanada R, Yamamo-
to K, Yokota J. Deletion map of chromosome 9 and p16 (CDKN2A)
gene alterations in neuroblastoma. Cancer Res 1997; 57: 907-12.
28. Niini T, Kanerva J, Vettenranta K, Saarinen-Pihkalla UM, Knuutila
S. AML1 gene amplification: a novel finding in childhood acute lym-
phoblastic leukemia. Haematologica 2000; 85: 362-6.
29. Cin PD, Atkins L, Ford C, Ariyanayagam S, Armstrong SA, George
R, Cleary A, Morton CC. Amplification of AML1 in childhood acute
lymphoblastic leukemia. Genes Chrom Cancer 2001; 30: 407-9. 
30. Coniat MB, Khac FN, Daniel MT, Bernard OA, Berger R. Chromo-
some 21 abnormalities with AML1 amplification in acute lymphoblas-
tic leukemia. Genes Chrom Cancer 2001; 32: 244-9.
31. Ma SK, Wan TS, Cheuk AT, Fung LF, Chan GC, Chan SY, Ha SY,
Chan LC. Characterization of additional genetic events in childhood
acute lymphoblastic leukemia with TEL/AML1 gene fusion: a molec-
ular cytogenetic study. Leukemia 2001; 15: 1442-7.
32. Alvarez Y, Coll MD, Bastida P, Ortega JJ, Caballin MR. AML1
amplification in a child with acute lymphoblastic leukemia. Cancer
Genet Cytogenet 2003; 140: 58-61.
. .
. .
. .
. . . .
. .
. .
′
′
′′ ′
′
′
′
′′
̃